Scythian Biosciences Corp. Announces Approval for Listing on the Nasdaq Capital Markets

Scythian Biosciences (TSXV:SCYB) is pleased to announce that the Company has received approval from the Nasdaq Capital Market to list its common shares on the Nasdaq. In honour of the listing, Scythian will ring the closing bell at the Nasdaq MarketSite in Times Square, New York City on February 22, 2018.

As quoted in the press release:

The common shares of the Company will commence trading on the Nasdaq at the opening of trading on February 22, 2018, under the trading symbol “SCYB”.

Jonathan Gilbert, Scythian’s CEO, commented, “We are pleased to have completed this major milestone. The Nasdaq listing represents greater accessibility and liquidity to a broader group of investors and increased market recognition, while our dual listing on the TSXV provides continued access to the investment community in Canada.”

Click here to read the full press release.